1. It is related to epidermal growth factor (EGF) and transforming growth factor alpha (TGF-alpha).

2. Disclosed is a skin repair enhancer containing EGF (epidermal growth factor), PDGF-AA (platelet-derived growth factor-AA) and IGF-1 (insulin-like growth factor 1).

3. Transforming growth factor alpha hii

4. The disclosed growth factor-mimicking peptides have the same functions or activities as a natural human growth factor.

5. Vascular endothelial growth factor(VEGF)is a specific vascular growth factor, which paly an important role in the angiogenesis .

6. Anti-adhesion polymer composition capable of supporting growth factor

7. Peptide showing growth factor activity, and use of same

8. Peptide having activity of transforming growth factor and production method therefor

9. Use of growth factor for regenerating damaged periodontal tissue and pulp tissue of extracted tooth, composition containing said growth factor as active ingredient, and kit for tissue regeneration

10. Give him insulin-like growth factor, make any tumor or malignancy grow.

11. Areg A gene on chromosome 4q13-q21 that encodes a member of the epidermal growth factor family, which is an autocrine growth factor and a mitogen for astrocytes, Schwann cells and fibroblasts

12. Polypeptides targeting vascular endothelial growth factor receptor-2 and alpha v beta 3 integrin

13. European scientists advanced knowledge in the field of growth factor signalling and related processes.

14. To determine the role of epidermal growth factor receptor (EGFR) signaling in endochondral ossification.

15. In contrast, an Auxotroph is a mutant unable to make a specific growth factor

16. Amphiregulin (Areg) is one of the ligands of the epidermal growth factor receptor (EGFR)

17. In pursuit of a regenerative wound therapy, we developed a heparin-based Coacervate delivery system that provides controlled release of heparin-binding epidermal growth factor (EGF)-like growth factor (HB-EGF) within the wound bed.

18. Issues which may distinguish the use of hematopoietic growth factors in AIDS as compared with in other clinical settings include: 1) interaction of the growth factor with other cytokines which are aberrantly expressed, 2) direct effects of the growth factor on the replicative activity of HIV, and 3) potential interactions of the growth factor with other concurrently administered medications.

19. The present invention discloses transforming growth factor alpha HII polypeptides and polynucleotides encoding such polypeptides.

20. Vascularization effect of basic fibroblast growth factor released from gelatin hydrogels with different Biodegradabilities Biomaterials

21. Wait until ANC # and platelets #; decrease dose by # % or continue full dose with growth factor support

22. Composition containing fibroblast growth factor-derived peptide fragments for wound healing or inhibiting skin wrinkle formation

23. Achondroplasia occurs due to a mutation in the gene for fibroblast growth factor receptor 3 (FGFR3).

24. PDGFB can exist as either Antiparallel disulfide-linked homodimers or heterodimers with Platelet-Derived Growth Factor Alpha

25. Achondroplasia is caused by a mutation in the fibroblast growth factor receptor-3 (FGFR-3) gene (3)

26. Objective To triturate the mixture epidermal growth factor suppositories to cure bact or trichomonas vaginitis and cervical erosion.

27. Achondroplasia is genetic disorder caused by a change (mutation) in the fibroblast growth factor receptor 3 (FGFR3) gene.

28. Use of Epidermal Growth Factor in the manufacture of a medicament for treating acne and acneiform dermal disorders.

29. Thyroid stimulating hormone (TSH) and epidermal growth factor (EGF) are growth factors for some thyroid cells in cultures.

30. Autocrine succinate signaling promotes retinal neovascularization, triggering the activation of angiogenic factors such as endothelial growth factor (VEGF).

31. Human Epidermal Growth Factor Receptor 2 Testing in 20 Does Chromosome 17 Centromere Copy Number Make Any Difference?

32. Amphiregulin (Areg) is a ligand of the epidermal growth factor receptor (EGFR), a widely expressed transmembrane tyrosine kinase

33. (Platelet Derived Growth Factor Beta Chain, NCI Thesaurus) The H1 helix packs orthogonally with the H2-H3 Antiparallel pair

34. It is a dual tyrosine kinase inhibitor which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways.

35. It is mainly used to treat cases of NSCLC that harbour mutations in the epidermal growth factor receptor (EGFR) gene.

36. Blastemas contain fibroblast growth factors, and may also contain neurotrophic factors such as nerve growth factor, brain-derived neurotrophic factor, neurotrophin 3, neurotrophin 4, glial cell line-derived neurotrophic factor and hepatocyte growth factor/scatter factor, since these factors are expressed in developing limbs in other vertebrates.

37. Achondroplasia is a condition that usually occurs due to gene alteration or mutation in the Fibroblast Growth Factor Receptor 3 gene.

38. Achondroplasia is a growth disorder of the bones caused due to a mutation in the fibroblast growth factor receptor 3 gene

39. Somatotropin also stimulates the release of another growth inducing hormone Insulin-like growth factor 1 (IGF-1) mainly by the liver.

40. A peptide formed from the amino acid sequence of SEQ ID NO: 1, according to the present invention, shows growth factor activity.

41. 19 Objective To evaluate the neurotropic effects of nerve growth factor (NGF) and regeneration chamber fluid (RCF) on the cultured nerve tissue.

42. Insulin-like growth factor 1 (IGF-1): This is a hormone that has both anabolic and anti-Catabolic effects on your muscles

43. Achondroplasia (ACH) is the most common form of dwarfism, caused by a genetic mutation in the fibroblast growth factor receptor 3 (FGFR3)

44. Amplifications of the epidermal growth factor receptor gene (egfr) are common in phyllodes tumors of the breast and are associated with tumor progression

45. AIM: To explore the effect of neural stem cells (NSC) transfected with vascular endothelial growth factor (VEGF) on brain injury irradiated by radioaction.

46. Achondroplasia, the most common of the skeletal dysplasias, is caused by a mutation in the gene expressing fibroblast growth factor receptor 3 (FGFR3)

47. The growth factor of the interface is found to depend not only on the wave number but also on the amplitude of the initial disturbance.

48. Currently, this database contains over 2 600 gene expression changes and information on hormones such as insulin-like growth factor (IGF), growth hormone and adrenocorticotropic hormone.

49. Objective: To investigate the effect of castration on the quantity of androgen receptor(AR) and the epidermal growth factor(EGF) in the submaxillary salivary glands of castrated rats.

50. Background: In 1994, achondroplasia, the most common form of chondrodysplasia, was shown to be caused essentially by one specific mutation in the fibroblast-growth-factor-receptor-3-gene (FGFR3).

51. 29 Objective: To investigate the effect of castration on the quantity of androgen receptor(AR) and the epidermal growth factor(EGF) in the submaxillary salivary glands of castrated rats.

52. 11 Objective: To investigate the effect of castration on the quantity of androgen receptor(AR) and the epidermal growth factor(EGF) in the submaxillary salivary glands of castrated rats.

53. The FGFR3 gene makes a protein called fibroblast growth factor receptor 3 that is involved in converting cartilage to bone.FGFR3 is the only gene known to be associated with Achondroplasia

54. On the other hand, there is promising data concerning the induction of therapeutic angiogenesis using the transfer of angiogenic genes such as the one for vascular endothelial growth factor VEGF.

55. At the same time, carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC) and tumor specific growth factor (TSGF) were also measured by microparticle enzyme immune analysis, bio-antibody sandwich, and chemo-Chromatometry.

56. The goal of treatment in acromegaly is to reduce growth hormone (GH) and age adjusted insulin-like growth factor 1 (IGF-1) levels and, where possible, to achieve normalization of the values.

57. Avidin represents a maximum of 0.05% of the total protein content of egg-white (Table 12.8). It is best known for its binding properties with biotin (vitamin H or B8), an essential growth factor

58. The recruitment and localization of eosinophils to specific sites of tissue inflammation involves cytokines with haematopoetic growth factor activity, adhesion molecules expressed both by the vascular endothelium and eosinophils, and chemoattractants that stimulate eosinophil migration.

59. After the completion of extensive preliminary animal experiments, the human angiogenetic growth factor FGF-1, obtained from a genetically transformed strain of E. coli was introduced into aortocoronary bypass surgery as an additional therapeutic agent.

60. Insulin and insulin-like growth factor I (IGF-I) receptors from carp ovaries were semipurified with wheat germ agglutinin at different moments of the reproductive cycle and their binding characteristics and tyrosine kinase activity were studied.

61. Amphiregulin (Areg) is a ligand of the epidermal growth factor receptor (EGFR), a widely expressed transmembrane tyrosine kinase. Areg is synthesized as a membrane-anchored precursor protein that can engage in juxtacrine signaling on adjacent cells.

62. The team also focused in the main on the genes and cascades known to be associated with tumour formation, including transforming growth factor-beta (TGF-beta), retinoblastoma protein (pRB), p53 and anaphase-promoting complex (APC) pathways.

63. The epidermal growth factor receptor (EGFR) is often overexpressed in non-small cell lung cancer (NSCLC) and considered to play a key role in carcinogenesis because of its effects on cell-cycle progression, apoptosis, angiogenesis, and metastasis.

64. Background Bintrafusp alfa is a first-in-class Bifunctional fusion protein composed of the extracellular domain of transforming growth factor (TGF)-βRII (a TGF-β ‘trap’) fused to a human IgG1 mAb blocking programmed cell death ligand 1

65. Biogenesis Hyper Protein is rich in natural vegan protein and contains vital branch chain amino acids (BCAAs). It’s rich in naturally occurring Chlorella Growth Factor (CGF) which promotes rapid building, repair and recovery of body and muscle tissue.

66. Acromegaly is a serious, chronic, and debilitating condition characterized by excessive secretion of human growth hormone (hGH) and elevation of serum insulin-like growth factor-I (IGF-I), usually resulting from a benign adenoma of the pituitary gland.

67. Since the novel 2,7-substituted thieno[3,2-d]pyrimidine compound exhibits superior inhibition activity against various protein kinases involved in growth factor signal transduction, it is useful as an agent for preventing or treating diseases caused by abnormal cell growth.

68. Rahimi’s Lab: Angiogenesis, formation of new blood vessels, plays central role in the pathology of numerous human diseases, including cancer and age-related macular degeneration.Angiogenesis is initiated by activation of vascular endothelial growth factor receptor-2 (VEGFR-2, also called KDR/FLK1).

69. M7824 (MSB0011359C) is a Bifunctional fusion protein composed of a monoclonal antibody against programmed death ligand 1 (PD-L1) fused to the extracellular domain of human transforming growth factor–β (TGF-β) receptor II, which functions as a “trap” for all three TGF-β isoforms

70. Autophagy, a cellular cleaning process, gets activated in response to certain types of metabolic stress, including nutrient deprivation, growth factor depletion and hypoxia.Even without adequate circulation, each cell may break down sub-cellular parts and recycle those into new proteins or energy as required to survive.

71. Bintrafusp alfa, a first-in-class Bifunctional fusion protein composed of the extracellular domain of the transforming growth factor (TGF)-βRII receptor (a TGF-β ‘trap’) fused to a human IgG1 antibody blocking programmed death ligand 1 (PD-L1), has shown clinical efficacy in multiple solid

72. Size, growth rate, adiposity, liver triacylglycerol and glycogen contents, and plasma insulin and insulin-like growth factor I (IGF-I) levels were monitored to follow the metabolic states of fish in the different treatment groups and to observe whether plasma levels of these growth mediators predict sexual development.

73. The first to enter in clinic has been Vitravene an Antisense oligonucleotide for the treatment of cytomegalovirus (CMV) infection and more recently, research on aptamers have led to the marketing of anti-vascular endothelial growth factor (VEGF) inhibitor (Macugen) for the treatment of age-related macular degeneration (AMD).

74. In samples from patients in the Arthralgic convalescent phase, we noted increases in IL-1β, IL-4, IL-6, IL-8, IL-9, IL-13, IL-15, GM-CSF, interferon-γ, tumor necrosis factor-α (TNF-α), RANTES, basic fibroblast growth factor (bFGF), macrophage inflammatory protein 1α (MIP1α), and VEGF in comparison to healthy controls.

75. It is also possible to provide a diagnostic for leukemia, pre-leukemia or an aleukemic malignant blood disease and a diagnostic for delayed take in hematopoietic stem cells after transplantation of the hematopoietic stem cells or graft versus host disease (GVHD) each containing as the active ingredient an antibody reacting with stem cell growth factor (SCGF).

76. The present invention relates to certain 2-(2,4,5-substituted-Anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M

77. In some lesions the inflammation may reflect viral influences (Kaposi sarcoma) or a bacterial infectious trigger (IgG4-related fibrosclerosing disease) whereas in others such an interaction is unclear and alterations in various genes have been detected, such as anaplastic lymphoma receptor tyrosine kinase gene rearrangements in inflammatory myofibroblastic tumor and platelet-derived growth factor receptor alpha (PDGFRA) gene mutations in inflammatory fibroid polyp and some gastrointestinal stromal tumors (GIST).

78. A method of judging leukemia, pre-leukemia or an aleukemic malignant blood disease characterized by comprising quantifying stem cell growth factor (SCGF); a method of discriminating leukemia from pre-leukemia or an aleukemic malignant blood disease; a method of discriminating aplastic anemia from myelodysplastic syndrome; a method of judging delayed take in hematopoietic stem cells after transplantation of the hematopoietic stem cells; and a method of judging graft versus host disease.